Search
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and...
Aug 12
IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year
Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets...
Aug 12
CytomX Therapeutics' years of work on its 'Probody' masking technology may be paying off at a time when there is growing focus on this approach - it presented key initial data on its EpCAM ADC in May
Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on...
Aug 11
Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease
CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the...
Aug 11
Astria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months
President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future...
Aug 7
From Indianapolis: Serial entrepreneur Derek Small publicly launched a new neuroscience company with $90M earlier this summer, Syndeio Biosciences. He tells us about it and talks Indiana biotech.
He discusses the idea behind Syndeio, which focuses on synaptic function and has a lead program in major depressive disorder. Plus, other...
Aug 5
From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat
CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA...
Aug 5
Former NIH Director and Co-Founder of ModeX Therapeutics Elias Zerhouni shares his take on possible NIH cuts and the state of science in the United States, and working on multispecifics at his company
He highlights his new memoir, Disease Knows No Politics, and gives his opinion on what is at stake in preserving NIH and other scientific...
Jul 30
AI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient
He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an...
Jul 24
Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders
The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications....
Jul 24
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out...
Jul 24
AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with...
Jul 23
AI x Bio Summit: The CEO of Alto Neuroscience, which is working on precision medicine for neuroscience, talks about how the company is using AI and machine learning in its development programs
Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is...
Jul 22
AI x Bio Summit: The Co-Founder and Head of Machine Learning at Dyno Therapeutics describes how his company is using AI to design better capsids
Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to...
Jul 22
AI x Bio Summit: Nimbus Therapeutics' new CEO and President of R&D describe how AI is, an isn't, used in the company's R&D process
CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and...
Jul 22
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the...
Jul 22
Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing
CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.
Jul 22
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs...
Jul 21
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic...
Jul 17
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive...
Jul 16
.png){kind=logo}
